GE HealthCare Earnings Call: Growth Holds, Margins Squeezed

Ge Healthcare Technologies Inc. ((GEHC)) has held its Q1 earnings call. Read on for the main highlights of the call.

GE HealthCare’s latest earnings call struck a cautiously optimistic tone, as management highlighted solid revenue growth, record backlog and meaningful product and M&A progress, while frankly acknowledging sharp near‑term pressure on margins and earnings. Executives expressed confidence that pricing, productivity and mix actions will gradually offset tariffs and material inflation, but emphasized that most of the benefit will arrive in the back half of 2026 rather than this year.

Revenue Beats Guidance on Solid Q1 Top-Line Growth

Q1 revenue reached $5.1 billion, landing at the high end of guidance and growing 2.9% organically year over year, despite a mixed macro backdrop and China softness. Both product and service lines outperformed on a reported basis, with product revenue up 7.3% and service revenue up 7.5%, underscoring broad-based demand across the portfolio.

Record Backlog and Orders Support Sales Outlook

Management underscored demand strength with a record $21.8 billion backlog, up $1.2 billion from a year ago and backed by a 1.07x book‑to‑bill ratio, which gives visibility into future revenue. Orders grew 1.1% and were sufficient for the company to reaffirm its full‑year organic sales guidance of 3% to 4%, suggesting resilience despite regional and cost headwinds.

Pharma Diagnostics and Imaging Lead Segment Performance

Pharmaceutical Diagnostics was a standout, delivering 9.7% organic growth as procedure volumes and radiopharmaceutical adoption remained strong. Imaging also posted healthy 3.8% organic growth, while Advanced Visualization Solutions grew 4.4% organically and expanded EBIT margin by about 120 basis points, signaling improving profitability in the software-heavy business.

High-Margin Services and Recurring Revenue Remain Robust

The company’s high-margin services franchise continued to be a key earnings and cash driver, with reported service revenue growing 7.5% year over year. This strength in recurring revenue helps cushion volatility in equipment cycles and supports free cash flow generation, an important factor given the current compression in overall margins.

Photonova and MR Wins Mark Product and Regulatory Progress

On the innovation front, GE HealthCare secured regulatory clearances for its Photonova Spectra photon‑counting CT systems in both the U.S. and Japan, a notable milestone in premium imaging. The company also highlighted multiple MR approvals, including a new 3T platform, reduced‑helium systems and AI workflow tools, with most new products now moving from clearance into early commercial orders.

Flyrcado Radiopharmaceutical Ramps Quickly

Momentum in radiopharmaceuticals was another bright spot, with Flyrcado doses up nearly 80% since late January and about 390 doses delivered in the week ended April 17. Management reiterated its medium‑term ambition for Flyrcado to exceed $500 million in annual revenue by 2028, emphasizing strong physician uptake and expanding site activation.

Strategic M&A and Segment Realignment Aim to Unlock Synergies

During the quarter, GE HealthCare closed the acquisition of Intelerad, bolstering its cloud and enterprise imaging capabilities and broadening its software footprint. The company also announced an organizational realignment that combines Imaging and ABS into a new Advanced Imaging Solutions segment, aiming to accelerate commercialization and better align R&D around integrated platforms.

Cash Generation Supports Debt Reduction and Buybacks

Free cash flow in Q1 came in at $112 million, improving by $13 million from the prior year as working capital remained disciplined despite growth investments. Management used this cash strength to repay $500 million of debt, repurchase roughly $100 million of shares and maintain its dividend, while updating the full‑year free cash flow outlook to around $1.6 billion.

Margins and EPS Squeezed Despite Operational Progress

Profitability lagged top‑line progress, with adjusted EBIT margin declining about 150 basis points year on year to 13.5% as costs outpaced pricing and productivity gains. Adjusted EPS of $0.99 fell short of expectations and included an estimated $0.16 hit from tariffs, reflecting the scale of external pressures facing the business.

Material Inflation Delivers a $250 Million Hit

Management quantified a roughly $250 million gross inflation impact this year, equal to about $0.43 per share, driven largely by surging memory chip prices and higher oil and freight costs, plus other commodities. While the company expects to offset more than half of this through price and cost actions, it still trimmed full‑year adjusted EPS guidance by $0.15 to reflect the remaining unmitigated pressure.

Patient Care Solutions Suffers from Volume and Timing Issues

Not all segments shared in the growth story, as Patient Care Solutions posted an 8.1% organic revenue decline and saw segment EBIT margin compress by about 500 basis points. Management cited timing of large monitoring installations and lower volumes as primary drivers, framing the weakness as partly transitory but still a notable drag on consolidated margins.

Supplier Recall Adds Extra Drag to Profits

Late‑quarter quality and recall issues linked to a Pharmaceutical Diagnostics supplier forced write‑offs and created a discrete profit headwind. Executives estimated the supplier-related disruption shaved roughly $0.05 off EPS, highlighting the operational sensitivity of the PDx supply chain even in a segment showing strong underlying demand.

Tariffs Remain a Persistent Margin Headwind

Tariffs were another major pressure point, materially affecting Q1 profitability and contributing about $0.16 of impact to adjusted EPS in the quarter alone. While management expects tariff headwinds to ease somewhat in 2026 versus 2025, the company is not baking potential refunds into its guidance, maintaining a conservative stance.

Cautious Stance on China Weighs on Outlook

China revenue declined year over year, though trends improved sequentially, reflecting ongoing macro and policy challenges in the region. Given the uncertainty, management has assumed China sales will be down for 2026 in its planning, signaling a cautious posture toward one of its historically important growth markets.

EPS Guidance Trimmed as Intelerad Adds Near-Term Dilution

Reflecting the layered impact of inflation, tariffs and segment-specific issues, GE HealthCare cut its full‑year adjusted EPS guidance to $4.80–$5.00, implying about 5% to 9% growth with Q2 EPS expected to decline low‑single‑digits year on year. The newly acquired Intelerad business is expected to be slightly dilutive to adjusted EPS in 2026 due to interest and integration costs, though management anticipates accretion beginning in 2027.

Guidance Balances Solid Growth with Cost Headwinds

For 2026, GE HealthCare maintained its 3% to 4% organic sales growth outlook, including similar growth for Q2, and expects about a 100‑basis‑point FX tailwind to revenue plus modest EBIT margin expansion to 15.4%–15.7%. Adjusted EPS is now guided to $4.80–$5.00 and free cash flow to around $1.6 billion, with management planning to offset more than half of a $250 million inflation hit and anticipating tariff pressure to be most acute in Q1 and lower than 2025 levels.

GE HealthCare’s call laid out a company executing well on revenue, innovation and strategic portfolio moves, but navigating a difficult earnings environment dominated by inflation, tariffs and specific operational issues. Investors are being asked to accept near‑term margin and EPS pressure in exchange for an improving medium‑term profile anchored by a record backlog, high‑growth segments like radiopharmaceuticals and a growing software and services mix.